ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1485

Characterization of Regulatory Receptors on Plasmacytoid Dendritic Cells in Lupus

Mark Jensen1, Ilona Nln1, Taro Iwamoto2, Jessica Dorschner3, Danielle Vsetecka3, Jacqueline Paredes1, Ruth Fernandez Ruiz4, Theresa Wampler Muskardin5 and Timothy Niewold1, 1Hospital for Special Surgery, New York, NY, 2Chiba University, New York, NY, 3Mayo Clinic, Rochester, 4Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 5Colton Center for Autoimmunity, NYU School of Medicine, New York, NY

Meeting: ACR Convergence 2022

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: To characterize regulatory surface receptors on blood plasmacytoid dendritic cells (PDCs) of lupus patients and controls to determine if receptor expression and function associates with disease activity or clinical characteristics in SLE.

Methods: Quantitative multicolor flow cytometry was used to measure immunoglobulin like transcript 7 (ILT7), bone marrow derived antigen 2 (BDCA2), ILT3, Fc epsilon receptor I (FcεRI), leukocyte-associated immunoglobulin-receptor 1 (LAIR1), natural killer cell P44-related protein (NKp44), bone marrow stromal cell antigen 2 (BST2), dendritic cell (DC) immunoreceptor (DCIR), and Fc gamma receptor IIa (FcγRII) on PDCs of peripheral blood mononuclear cells (PBMC) from 65 SLE patients and 15 controls. For functional studies, PBMC from 9 SLE and 9 controls were treated with ILT7 and BDCA2 crosslinking antibodies followed by TLR9 agonists.

Results: Significant associations were found between multiple receptors, IFN levels, SLEDAI scores, and autoreactive antibody titers. ILT7 expression correlated inversely with SLEDAI, and ANA titers. High IFN SLE patients had increased levels of the ILT7 ligand BST2 and at the same time reduced ILT7 expression. BDCA2 levels were 5-fold higher than ILT7 levels, and were also inversely correlated with SLEDAI. Crosslinking ILT7 only weakly inhibited IFN secretion. Crosslinking BDCA2 significantly reduced IFN production in SLE patient cells, but this was much greater in patients with low SLEDAI scores than those with high SLEDAI scores.

Conclusion: We identify associations between PDC regulatory receptors and clinical disease in lupus patients, and dominant inhibitory function of BDCA2 over ILT7 in pDC type I IFN secretion with dependency upon disease activity.


Disclosures: M. Jensen, None; I. Nln, None; T. Iwamoto, None; J. Dorschner, None; D. Vsetecka, None; J. Paredes, None; R. Fernandez Ruiz, None; T. Wampler Muskardin, None; T. Niewold, None.

To cite this abstract in AMA style:

Jensen M, Nln I, Iwamoto T, Dorschner J, Vsetecka D, Paredes J, Fernandez Ruiz R, Wampler Muskardin T, Niewold T. Characterization of Regulatory Receptors on Plasmacytoid Dendritic Cells in Lupus [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/characterization-of-regulatory-receptors-on-plasmacytoid-dendritic-cells-in-lupus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-regulatory-receptors-on-plasmacytoid-dendritic-cells-in-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology